OHR Pharmaceutical Inc.

Overview

Company Info

Ohr Pharmaceutical, Inc. (NASDAQ: OHRP)

Ohr Pharmaceutical, Inc. (NasdaqCM:OHRP) is a pharmaceutical company focused on the development of novel therapeutics and delivery technologies for the treatment of ocular diseases. Our lead clinical program, OHR-102 (Squalamine) eye drops, which is entering pivotal Phase III clinical trials, is a novel anti-angiogenic product that provides a non-invasive therapy which in Phase II studies has been shown to improve visual outcomes compared to the current gold standard monotherapy treatments without requiring additional injections. We also have several products in preclinical development utilizing our patented sustained release delivery technology for other common ocular indications including glaucoma, ocular allergy, and retinal diseases.

Webcast of Ohr Pharmaceutical Presentation at 2017 Marcum Microcap Conference

Contact Info

Company Information

Ohr Pharmaceutical, Inc.
800 Third Avenue
11th Floor
New York, NY 10022

Investor Relations

LifeSci Advisors
Michael Rice
646-597-6979
mrice@lifesciadvisors.com

Stock Info

OHRP
NASDAQ

Q2 2017 Quarterly Results

Recent News